Personal Finance

3 High-Growth ETFs to Supercharge Your Portfolio

Getty Woman Checking Reports
Getty Woman Checking Reports

Exchange-traded funds, or ETFs, are a smart and easy way to gain exposure to a variety of sectors with far-less downside risk than individual stocks. If you want exposure to high-growth stocks, but don't trust your stock-picking skills, or don't want to put too many eggs in one basket, you'll find a vast selection of ETFs that you can buy and sell right from your discount-brokerage account. And they typically charge far less than old-fashioned mutual funds.

We've asked three Motley Fool contributors to discuss a favorite high-growth ETF that they feel are best poised to supercharge a portfolio. Here's what they had to say.

Large-cap growth, teeny-tiny fees

Matt Frankel: One of my favorite high-growth ETFs is the Vanguard Growth ETF (NYSEMKT: VUG) , which is a passively managed fund that replicates the CRSP U.S. Large Cap Growth Index. Essentially, this fund allows investors to invest in the largest growth stocks in the market without the guesswork of choosing individual stocks.

For starters, I like this option because it's cheap . The fund has a remarkably small 0.08% expense ratio, which is 93% less than the average of similar funds. And there's a modest, but significant, dividend yield of 1.42%, because many of the larger growth companies are dividend payers.

The fund is weighted, which could be a good or a bad thing, depending on how you look at it. In other words, more of your money will be invested in larger companies such as Apple , Alphabet (Google), Facebook , and . In fact, even though the fund owns 336 stocks, the 10 largest holdings make up 26.7% of the assets.

This could be good if you want lots of exposure to companies like these. It could also be a bad thing if you actually want to invest in smaller growth companies such as Wynn Resorts or Fitbit , which combine to make up less than 0.05% of the fund's assets.

A cheap way to buy into a high-growth industry

Brian Feroldi: The biotechnology sector has been on fire for years, far outpacing the growth of the S&P 500 , in general. An investor who is looking to turbo charge a portfolio's upside potential should consider buying an ETF that's focused on the space. One of my favorites is the SPDR S&P Biotech ETF (NYSEMKT: XBI) .

As its name suggests, this fund's strategy is to invest in a basket of biotech stocks. It currently holds a position in about 90 different companies.

One unique feature of this fund that separates it from other biotech ETFs is that if follows an equal-weight strategy. That means that it invests the same amount of capital into each of the companies that it buys, rebalancing itself each quarter. This strategy prevents the fund from becoming overly concentrated in just a handful of stocks.

A look at its long-term performance shows that XBI has stumbled upon a winning formula. Since it first hit the markets in 2006, the XBI is up more than 240%, which smashes the returns of the S&P 500.

XBI data by YCharts .

If that amazing growth wasn't enough of a reason to invest, the XBI is pretty cheap to own, too. Its expense ratio is only 0.35%, making it one of the lowest-cost biotech ETFs out there.

As the chart above indicates, this fund -- like the rest of the biotechnology sector -- has had a rough year, falling dramatically from its 2015 highs. That's thanks to investors fleeing from the biotech sector for a variety of reasons , all of which I think are short-term in nature.

With the biotech sector currently out of favor, I think that right now is a great time for investors to consider jumping in. The XBI is my favorite choice as a way to get started.

An ultra-focused high-growth ETF

Cory Renauer : If you're looking for exposure to the most-exciting segment of the biotechnology industry -- immuno-oncology -- the Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR) is for you.

Researchers suggested that tumors employ different means to avoid the immune system decades ago. However, it wasn't until 2011 when the first major drug to exploit one of these pathways, Yervoy from Bristol-Myers Squibb , earned FDA approval.

INO Chart

INO data by YCharts .

At the end of June, the fund's managers will sell off enough Inovio shares to reduce its proportion from about 6.9% to 3.3% total assets. It will also purchase enough shares of Celldex to bring it up from about 1.2% at present to 3.3% of total assets.

Of course, it could cut either one from the index entirely to make room for better companies. Given Celldex stock 's potential, I think the fund will keep it.

In return for reading the scientific literature, attending conferences, then choosing the 30 best-positioned immuno-oncology companies, the fund charges 0.79% of assets under management. This makes it the most-expensive fund of these three; but I think it's worth every penny.

A secret billion-dollar stock opportunity

The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More